Finance Updates – Finance Updates

Parabilis Raises $305M Series F to Advance Zolucatetide into Rare Tumor Trials

Americas Firms Pharmaceutical and Medicine Manufacturing

Parabilis Medicines raised $305 million in a ...

The cash will advance FOG-001 (zolucatetide),...

Its Helicon platform uses stabilized, cell-pe...

Near-term upside centers on rare-tumor regula...

Lilly Pays $1.2B for Ventyx to Boost Oral NLRP3 Inhibitor Pipeline

Americas M&A Pharmaceutical and Medicine Manufacturing

Eli Lilly will acquire Ventyx Biosciences for...

The deal bolsters Lilly’s oral inflammation p...

Ventyx’s lead CNS-penetrant NLRP3 inhibitor V...

A second asset, peripheral NLRP3 inhibitor VT...

Global Pharma M&A Shifts: Mid-Market Deals, Regional Opportunity & Regulatory Risks

Global M&A Pharmaceutical and Medicine Manufacturing

FounderNest data on 1,489 pharma M&A deals (~...

Deal value rebounded in Q1 2025 to US$37.7B (...

Large pharma is favoring mid-sized bolt-on ac...

Pricing, tariff, regulatory, and cross-border...